Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus platinum-doublet chemotherapy followed by tongue-conserving surgery for locally advanced tongue squamous cell carcinoma
ChiCTR2400079379Phase 2Recruiting
- Sponsor
- Peking University School of Stomatology
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cisplatin and paclitaxel in squamous cell carcinoma of the tongue (TSCC), sponsored by Peking University School of Stomatology. Primary endpoint: 1-year event-free survival. Started Jan 2024; status: recruiting.
02
Drugs
tislelizumabcisplatinpaclitaxel
03
Conditions
squamous cell carcinoma of the tongue (TSCC)
Beyond the preview
Go deeper on ChiCTR2400079379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079379.